top of page

New Perspectives on Diagnosis and Treatment of EGFR Exon 20 Insertion-Mutant NSCLC ~ 0.75 CNE

FREE Offering! Click here to check it out!


An estimated 235,760 new cases of lung cancer are reported in the United States annually, and 131,880 people die of the disease. Approximately 84% of cases are classified as non-small cell lung cancer (NSCLC) (ACS, 2021). The most frequent genomic aberration among patients with NSCLC is the epidermal growth factor receptor (EGFR) mutation, approximately 2%-10% of which are exon 20 insertion mutations (Kumari et al, 2019; Dersarkissian et al, 2019). Exon 20 insertion mutations are a heterogenous group frequently associated with resistance to first- and second-line EGFR tyrosine kinase inhibitor (TKI) therapy (NCCN, 2021). Currently, there are no approved therapies specifically designed to treat EGFR exon 20 insertion–mutant NSCLC (LCRF, 2020). There is an unmet need to develop effective targeted therapies to improve outcomes and quality of life in patients with this disease.


Oncologists, pulmonologists, pathologists, histologists, and other health care professionals involved in the treatment of patients with non-small cell lung cancer (NSCLC).


Upon completion of this activity, participants should be able to:

  • Discuss the predictive/prognostic significance of EGFR exon 20 insertions in NSCLC

  • Evaluate the benefits and limitations of polymerase chain reaction and next-generation sequencing in diagnosis of EGFR exon 20 insertion–mutant NSCLC

  • Assess emerging efficacy and safety data on novel targeted therapies for advanced EGFR exon 20 insertion–mutant NSCLC

15 views0 comments

Recent Posts

See All

Cancer Equity Colloquium 2024

Now more than ever, the presence of social inequities in healthcare is evident. This two-day, hybrid event, the Cancer Equity Colloquium, will address the diverse issues that underlie cancer inequitie


bottom of page